Safety and ragional differences of Isatuximab- pomalidomide-dexamethasone combination in relapsed/refractory multiple myeloma: an external validation using FAERS and Lecheng real-world database
Abstract Isatuximab approved by FDA in 2020 for the treatment of relapsed and refractory multiple myeloma (RRMM), although ICARIA-MM trial established its efficacy, leaving gap in different regional healthcare systems and reporting methodologies. This study investigated the AE profile of Isatuximab combined with pomalidomide-dexamethasone (Isa-Pd), focusing on safety of Isa-Pd, and regional differences between Lecheng and French in FAERS (FR). Lecheng data (2022Q3–2024Q2) were extracted from a prospective observational real-world study in China (IsaFiRsT), while FAERS reports (2020Q1–2025Q4) were obtained from the FDA Adverse Event Reporting System database. AE terms were standardized using MedDRA, and data mining used ROR, PRR, BCPNN, and MGPS algorithms. Our study divided into 2 parts: 1. Analysis all Isa-Pd-related data in FAERS and Lecheng. 2. Comparing the database of French in FAERS with Lecheng to get regional differences. A total of 507 AE reports were analyzed, with 200 reports from Lecheng and FR used for regional comparison. Strong overall signals included infections and infestations, blood/lymphatic system disorders, investigations, and cardiac disorders. Beyond known hematological toxicities, this study identified unexpected risk signals, including cardiac failure, hypertension, hypokalemia, and Pneumocystis jirovecii pneumonia, which are not fully characterized in current prescribing information. No specific fatal risk was attributed to Isa-Pd. Regional differences were observed between Lecheng and FR: Lecheng group had more males (Lecheng 62.5% vs FR 48.21%), and lderly patients(≥65 years: Lecheng 70.45% vs FR 58.93%). AEs reported group show difference, all data in Lecheng by physicians, and FR data reported almost equally by pharmacist (56.25%) and physician (42.86%). Lecheng shows frequent hospitalization (100%) in outcome, while FR showed a broader outcome spectrum (hospitalization 53.57%, Life-Threatening 12.50%, death 4.5%). Onset was shorter in Lecheng (Median Lecheng 9.50 vs FR 13.50), Lecheng AE signals concentrated in Investigations (Neutrophil count decreased, ROR=172.21; Platelet count decreased, ROR=22.75). FR group AE signals distributed across Blood and lymphatic system disorders (Lymphopenia, ROR=58.15; Neutropenia, ROR=31.76), Infections and infestations (COVID-19, ROR=12.11), and Vascular disorders (Hypertension, ROR=18.28). These regional differences may be related to population variations, regional management, and distinct post-AE medication regimens. Crucially, by introducing a prospective local real-world cohort (Lecheng) as an external validation for FAERS, this study overcomes the inherent under-reporting biases of spontaneous systems. It comprehensively characterizes the Isa-Pd safety profile, uncovers unexpected risks, and provides robust pharmacological evidence for individualized safety monitoring and risk mitigation.
Authors
- Qiaoqiao Chen (ORCID: https://orcid.org/0000-0002-3409-5402)
- Li-Qun Zhang (ORCID: https://orcid.org/0000-0003-1452-203X)
- You Jian-Hua
- Zi-yin Huang
- Xin-Xin Chen
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-13
- DOI
- https://doi.org/10.21203/rs.3.rs-11525112/v1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- preprint